126 related articles for article (PubMed ID: 22901566)
21. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):191-6. PubMed ID: 26857022
[TBL] [Abstract][Full Text] [Related]
22. Comparative study of total prostate specific antigen and free to total prostate specific antigen ratio in the diagnosis of prostate cancer.
Chakraborty L; Ahmed AN; Paul BK; Haque A; Ara A; Nabi S; Nessa M
Mymensingh Med J; 2012 Jan; 21(1):98-102. PubMed ID: 22314462
[TBL] [Abstract][Full Text] [Related]
23. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
24. The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: a validation study on a Turkish patient population in different age categories.
Erol B; Gulpinar MT; Bozdogan G; Ozkanli S; Onem K; Mungan G; Bektas S; Tokgoz H; Akduman B; Mungan A
Kaohsiung J Med Sci; 2014 Nov; 30(11):545-50. PubMed ID: 25458043
[TBL] [Abstract][Full Text] [Related]
25. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
26. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
[TBL] [Abstract][Full Text] [Related]
27. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Magklara A; Scorilas A; Catalona WJ; Diamandis EP
Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
[TBL] [Abstract][Full Text] [Related]
28. Clinical usefulness of free PSA in early detection of prostate cancer.
Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
[TBL] [Abstract][Full Text] [Related]
29. Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study.
Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Rodríguez-Melcón JI; Herrera-Ramos E; Rodríguez-Gallego C; Lara PC
Urol Oncol; 2015 Jul; 33(7):331.e1-7. PubMed ID: 25960412
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
Okihara K; Cheli CD; Partin AW; Fritche HA; Chan DW; Sokoll LJ; Brawer MK; Schwartz MK; Vessella RL; Loughlin KR; Johnston DA; Babaian RJ
J Urol; 2002 May; 167(5):2017-23; discussion 2023-4. PubMed ID: 11956430
[TBL] [Abstract][Full Text] [Related]
31. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
32. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
[TBL] [Abstract][Full Text] [Related]
33. Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
Letran JL; Blase AB; Loberiza FR; Meyer GE; Ransom SD; Brawer MK
J Urol; 1998 Aug; 160(2):426-9. PubMed ID: 9679891
[TBL] [Abstract][Full Text] [Related]
34. Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.
Thakur V; Singh PP; Talwar M; Mukherjee U
Dis Markers; 2003-2004; 19(6):287-92. PubMed ID: 15258330
[TBL] [Abstract][Full Text] [Related]
35. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
36. KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness.
Lin HY; Huang PY; Cheng CH; Tung HY; Fang Z; Berglund AE; Chen A; French-Kwawu J; Harris D; Pow-Sang J; Yamoah K; Cleveland JL; Awasthi S; Rounbehler RJ; Gerke T; Dhillon J; Eeles R; Kote-Jarai Z; Muir K; ; Schleutker J; Pashayan N; ; Neal DE; Nielsen SF; Nordestgaard BG; Gronberg H; Wiklund F; Giles GG; Haiman CA; Travis RC; Stanford JL; Kibel AS; Cybulski C; Khaw KT; Maier C; Thibodeau SN; Teixeira MR; Cannon-Albright L; Brenner H; Kaneva R; Pandha H; ; Srinivasan S; Clements J; Batra J; Park JY
Sci Rep; 2021 Apr; 11(1):9264. PubMed ID: 33927218
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
[TBL] [Abstract][Full Text] [Related]
38. Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels.
Dinçel C; Caşkurlu T; Taşçi AI; Cek M; Sevin G; Fazlioğlu A
Int Urol Nephrol; 1999; 31(4):497-509. PubMed ID: 10668945
[TBL] [Abstract][Full Text] [Related]
39. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
[TBL] [Abstract][Full Text] [Related]
40. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript.
Kote-Jarai Z; Amin Al Olama A; Leongamornlert D; Tymrakiewicz M; Saunders E; Guy M; Giles GG; Severi G; Southey M; Hopper JL; Sit KC; Harris JM; Batra J; Spurdle AB; Clements JA; Hamdy F; Neal D; Donovan J; Muir K; Pharoah PD; Chanock SJ; Brown N; Benlloch S; Castro E; Mahmud N; O'Brien L; Hall A; Sawyer E; Wilkinson R; Easton DF; Eeles RA
Hum Genet; 2011 Jun; 129(6):687-94. PubMed ID: 21465221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
